Agilent Receives FDA Approval For The PD‑L1 LHC 28‑8 PharmDx Assay As Companion Diagnostic To Identify Patients With Carcinomas Who May Be Eligible For Treatment With OPDIVO or OPDIVO QVANTIG

Loading news article.

Agilent Receives FDA Approval For The PD‑L1 LHC 28‑8 PharmDx Assay As Companion Diagnostic To Identify Patients With Carcinomas Who May Be Eligible For Treatment With OPDIVO or OPDIVO QVANTIG | WAPE

Agilent Receives FDA Approval For The PD‑L1 LHC 28‑8 PharmDx Assay As Companion Diagnostic To Identify Patients With Carcinomas Who May Be Eligible For Treatment With OPDIVO or OPDIVO QVANTIG

Article summary

Related companies

Comments —